MX2012004092A - Sistema de expresion. - Google Patents

Sistema de expresion.

Info

Publication number
MX2012004092A
MX2012004092A MX2012004092A MX2012004092A MX2012004092A MX 2012004092 A MX2012004092 A MX 2012004092A MX 2012004092 A MX2012004092 A MX 2012004092A MX 2012004092 A MX2012004092 A MX 2012004092A MX 2012004092 A MX2012004092 A MX 2012004092A
Authority
MX
Mexico
Prior art keywords
expression system
toxin
crm197
compositions
methods related
Prior art date
Application number
MX2012004092A
Other languages
English (en)
Inventor
Denis Martin
Normand Blais
Philippe Marc Helene Dehottay
Marianne Dewerchin
Philippe Goffin
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41402733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012004092(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MX2012004092A publication Critical patent/MX2012004092A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved

Abstract

Se proporcionan en la presente memoria composiciones y procedimientos relacionados con la expresión periplásmica de una toxina, incluyendo toxina diftérica o CRM197.
MX2012004092A 2009-10-08 2010-10-07 Sistema de expresion. MX2012004092A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0917647.0A GB0917647D0 (en) 2009-10-08 2009-10-08 Expression system
PCT/EP2010/065047 WO2011042516A2 (en) 2009-10-08 2010-10-07 Expression system

Publications (1)

Publication Number Publication Date
MX2012004092A true MX2012004092A (es) 2012-04-20

Family

ID=41402733

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012004092A MX2012004092A (es) 2009-10-08 2010-10-07 Sistema de expresion.
MX2014014686A MX347256B (es) 2009-10-08 2010-10-07 Sistema de expresión.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014014686A MX347256B (es) 2009-10-08 2010-10-07 Sistema de expresión.

Country Status (17)

Country Link
US (4) US9422345B2 (es)
EP (3) EP2486047B1 (es)
JP (3) JP2013507113A (es)
KR (1) KR20120099672A (es)
CN (1) CN102639558B (es)
AR (1) AR078533A1 (es)
AU (1) AU2010305342B2 (es)
BR (1) BR112012007984B1 (es)
CA (1) CA2776969C (es)
EA (1) EA201290134A1 (es)
ES (2) ES2750023T3 (es)
GB (1) GB0917647D0 (es)
IL (1) IL218930A0 (es)
MX (2) MX2012004092A (es)
SG (1) SG10201405940VA (es)
UY (1) UY32933A (es)
WO (1) WO2011042516A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0917647D0 (en) * 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
NZ602958A (en) 2010-03-30 2014-07-25 Pfenex Inc High level expression of recombinant toxin proteins
WO2012025873A2 (en) 2010-08-23 2012-03-01 Wyeth Llc STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS
PE20140173A1 (es) 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
GB201106225D0 (en) * 2011-04-13 2011-05-25 Glaxosmithkline Biolog Sa Fermentation process
SG10201602558UA (en) 2012-03-09 2016-05-30 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US10287330B2 (en) 2012-12-27 2019-05-14 Glaxosmithkline Biologicals S.A. Methods and compositions relating to CRM197
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11060123B2 (en) 2014-01-31 2021-07-13 Fina Biosolutions, Llc Production of soluble recombinant protein without n-terminal methionine
US10093704B2 (en) 2014-01-31 2018-10-09 Fina Biosolutions, Llc Expression and purification of CRM197 and related proteins
US10479820B2 (en) 2014-03-03 2019-11-19 Scarab Genomics, Llc Enhanced production of recombinant CRM197 in E. coli
MA39746A (fr) 2014-03-14 2021-04-28 Hoffmann La Roche Compositions de sécrétion de polypeptides hétérologues et procédés associés
EP3221339A1 (en) * 2014-11-20 2017-09-27 Biological E Limited Codon optimized polynucleotide for high level expression of crm197
BR112017017460A2 (pt) 2015-02-19 2018-04-10 Pfizer Inc. composições de neisseria meningitidis e métodos das mesmas
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR101908590B1 (ko) * 2017-02-01 2018-10-16 (주)포바이오코리아 Crm197의 용해성 단백질 발현 및 정제 방법
EP3444269A1 (en) 2017-08-17 2019-02-20 National Research Council of Canada Systems and methods for the production of diphtheria toxin polypeptides
WO2019043593A1 (en) * 2017-09-01 2019-03-07 Lorven Biologics Private Limited NUCLEIC ACID ENCODING CRM197 AND ENHANCED EXPRESSION PROCESS THEREOF
CA3074718A1 (en) 2017-09-05 2019-03-14 Scarab Genomics, Llc Methods and compositions for improved expression of recombinant proteins
CN111278852A (zh) 2017-10-27 2020-06-12 菲尼克斯公司 重组欧氏杆菌天冬酰胺酶的生产方法
JP2021501157A (ja) * 2017-10-27 2021-01-14 フェネックス インク． 周辺タンパク質発現のための細菌リーダー配列
CA3084436A1 (en) 2017-12-06 2019-07-18 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
KR102059619B1 (ko) 2018-04-17 2019-12-26 강원대학교산학협력단 글루코스-자일로스 혼합당의 동시발효가 가능한 돌연변이 균주
WO2020033398A1 (en) * 2018-08-06 2020-02-13 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating atii cell-dependent lung diseases
AU2019401535B2 (en) 2018-12-19 2023-12-14 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
EP3942079A1 (en) 2019-03-18 2022-01-26 Bio-Rad ABD Serotec GmbH Protection of spytag-containing periplasmic fusion proteins from protease tsp and ompt degradation
KR102099342B1 (ko) * 2019-09-03 2020-04-10 주식회사 제노포커스 Crm197 단백질 발현 방법
BE1029145B1 (fr) 2021-02-26 2022-09-27 Curavac Europe Methode de production d'une forme periplasmique de la proteine crm197

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
DE3071552D1 (en) 1979-09-21 1986-05-22 Hitachi Ltd Semiconductor switch
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
JPS62158491A (ja) * 1985-12-28 1987-07-14 Wakunaga Pharmaceut Co Ltd 精製蛋白質の製造法
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
EP0460021A4 (en) * 1989-02-23 1992-08-26 Seragen, Inc. Chimeric toxin
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
GB2253210B (en) * 1991-02-26 1995-06-07 Ici Plc Soluble heterologous polypeptide produced by culture of recombinant microorganisms
ATE245446T1 (de) 1992-02-11 2003-08-15 Jackson H M Found Military Med Dualer träger für immunogene konstrukte
JP3506431B2 (ja) 1992-05-06 2004-03-15 プレジデント アンド フェローズ オブ ハーバード カレッジ ジフテリア毒素受容体結合領域
NZ253065A (en) 1992-05-23 1996-10-28 Smithkline Beecham Biolog Combination vaccines comprising hepatitis b surface antigens and other antigens wherein aluminium phosphate adjuvant is used to adsorb the hepatitis antigen
AU671649B2 (en) 1992-06-18 1996-09-05 President And Fellows Of Harvard College Diphtheria toxin vaccines
AU678613B2 (en) 1993-09-22 1997-06-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
ATE241384T1 (de) 1995-03-22 2003-06-15 Jackson H M Found Military Med Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
SI1082965T1 (sl) 1995-06-23 2009-08-31 Glaxosmithkline Biolog Sa Sestavek cepiva, ki vsebuje antigen konjugata polisaharida, adsorbiranega na aluminijevem fosfatu
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
KR100401423B1 (ko) 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
US7424370B2 (en) * 2004-02-06 2008-09-09 Council Of Scientific And Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
ATE448305T1 (de) * 2005-07-08 2009-11-15 Univ Zuerich Phagen-display mittels cotranslationaler translokation von fusionspolypeptiden
GB0917647D0 (en) * 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system

Also Published As

Publication number Publication date
JP2017029155A (ja) 2017-02-09
US20180258146A1 (en) 2018-09-13
EA201290134A1 (ru) 2012-10-30
AR078533A1 (es) 2011-11-16
EP3480209A3 (en) 2019-06-19
JP2018085994A (ja) 2018-06-07
SG10201405940VA (en) 2014-11-27
AU2010305342A1 (en) 2012-05-03
EP2486047A2 (en) 2012-08-15
IL218930A0 (en) 2012-07-31
CN102639558A (zh) 2012-08-15
CA2776969A1 (en) 2011-04-14
BR112012007984A2 (pt) 2016-11-22
JP2013507113A (ja) 2013-03-04
MX347256B (es) 2017-04-20
CA2776969C (en) 2019-01-15
UY32933A (es) 2011-05-31
WO2011042516A3 (en) 2011-06-16
EP2486047B1 (en) 2016-10-05
US20120289688A1 (en) 2012-11-15
AU2010305342B2 (en) 2016-05-26
EP3170837A3 (en) 2017-07-19
JP6305478B2 (ja) 2018-04-04
US9422345B2 (en) 2016-08-23
CN102639558B (zh) 2015-11-25
EP3480209A2 (en) 2019-05-08
EP3170837A2 (en) 2017-05-24
US20190322708A1 (en) 2019-10-24
EP3480209B1 (en) 2023-11-29
EP3170837B1 (en) 2019-08-21
ES2750023T3 (es) 2020-03-24
WO2011042516A2 (en) 2011-04-14
BR112012007984B1 (pt) 2021-11-03
GB0917647D0 (en) 2009-11-25
US20170137475A1 (en) 2017-05-18
JP6636546B2 (ja) 2020-01-29
US9994622B2 (en) 2018-06-12
ES2609066T3 (es) 2017-04-18
KR20120099672A (ko) 2012-09-11

Similar Documents

Publication Publication Date Title
MX347256B (es) Sistema de expresión.
MX2018008597A (es) Composiciones inyectables de melfalan que comprenden un derivado de ciclodextrina y metodos de fabricacion y uso de las mismas.
PH12015501470A1 (en) Compositions and methods for the control of nematodes and soil borne diseases
MX342709B (es) Tratamiento contra el cancer.
GB2493292A (en) Fibrous structures and methods for making same
IL218075A0 (en) Methods of treating cancer using tachykinin retargeted endopeptidases
IN2012DN00746A (es)
SMT201500211B (it) Procedimento di coniugazione di polisaccaridi batterici a proteine di trasporto
HK1180592A1 (zh) 可降解的梭狀芽孢桿菌毒素
MX2013002417A (es) Composiciones pesticidas.
MX344786B (es) Composiciones y metodos para tratar enfermedad de gaucher.
BRPI1007339A2 (pt) Dispositivos médicos e métodos
IN2011KN03851A (es)
DK3460056T3 (da) Terapeutiske nukleasesammensætninger og fremgangsmåder
GB201020616D0 (en) Device for imparting distance information
HK1188385A1 (zh) 腦膜炎奈瑟球菌 抗原的非脂質化變體
EP2287300A4 (en) BACTERIA TOXIN VACCINE
MX2009010081A (es) Metodos y composiciones relacionadas con los ribointerruptores (riboswitches) que controlan el corte y empalme (splicing) alternativo.
GB0911380D0 (en) Maritube - floating algal cultivation system
EP2663338A4 (en) OLIGOSACCHARIDIC CONJUGATES FOR TARGETING BACTERIA AND USES THEREOF
IN2012DN03404A (es)
UA112760C2 (uk) Теобромін у комбінації з гвайфенезином для лікування кашлю
GB0916957D0 (en) Floagal-floating algal cultivation system
EP2329029A4 (en) METHOD AND COMPOSITIONS FOR INCREASING TOXIN PRODUCTION
GT201200082A (es) Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal